March 28, 2025 Kigali, Rwanda and San Francisco, USA

Yesterday, during our ongoing mission in Senegal, the Bio Usawa team met with officials from the Ministry of Health and Agence Sénégalaise de Réglementation Pharmaceutique (ASRP) to discuss the burden of Non-Communicable Diseases in the country and regulatory pathways for biologics, quality control standards, and requirements for product registration in Senegal. These discussions are critical to ensuring that locally manufactured monoclonal antibodies meet international quality and safety standards while accelerating their availability to patients.

This visit underscores Bio Usawa’s commitment to advancing health equity and biopharmaceutical sovereignty in Africa, aligning with its mission to address critical gaps in severe and infectious disease treatment.

About Bio Usawa, Inc. (BUI)

Bio Usawa has a singular mission: to manufacture high-quality, effective and affordable biosimilars for patients in Africa. We are applying our 100+ years of combined experience in the industry in partnership with governments, agencies, educators and health professionals to make transformative biomedicines in Africa, by Africans, for Africans and beyond. 

Click here to learn more about our company's recent successes and download our new White Paper on Regulatory Approaches to Biosimilars in Africa.